Washington, D.C. 20549






Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): September 2, 2015





(Exact name of registrant as specified in its charter)


Nevada 000-55016 26-0690857
(State or other jurisdiction of incorporation or organization) (Commission File Number)

IRS Employer

Identification No.)


655 Montgomery Street, Suite 900

San Francisco, CA

(Address of Principal Executive Offices) (Zip Code)


(408) 737-2734

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 5.07 Submission of Matters to a Vote of Security Holders


On September 2, 2015, Amarantus Bioscience Holdings, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”).  An aggregate of 6,355,474 shares held by holders of the Company’s voting stock , constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on July 21, 2015, as supplemented, are as follows:


Proposal 1.  All of the six (6) nominees for director were elected to serve until the 2016 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the eight (8) directors was as follows:


Directors   For   Against   Abstain Broker Non Vote
Gerald E. Commissiong   5,718,696   0   636,778 0
Dr. John W. Commissiong   6,161,979   0   193,495 0
Robert L. Harris   6,165,496   0   189,978 0
Dr. David A. Lowe   6,192,619   0   162,855 0
Donald Huffman   6,192,347   0   163,127 0
Dr. Joseph Rubinfeld   6,159,487   0   195,987 0


Proposal 2. The appointment of Marcum, LLP as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2015 was ratified and approved by the stockholders by the votes set forth in the table below:


For   Against   Abstain   Broker Non Vote  
6,249,398   78,812   27,264   0  


Proposal 3.  The adoption of an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of common stock to 35,000,000 from 13,333,334 was ratified and approved by the stockholders by the votes set forth in the table below:


For   Against   Abstain   Broker Non Vote  
5,602,502   710,547   42,425   0  


The Company issued a press release with respect to the foregoing, a copy of which is attached hereto as Exhibit 99.1.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.   Description



Press Release dated September 3, 2015







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: September 3, 2015 By: /s/ Gerald E. Commissiong
    Name: Gerald E. Commissiong
    Title: Chief Executive Officer